MabVax Gets $1.1M Grant

Xconomy San Diego — 

MabVax Therapeutics, a San Diego clinical stage biotechnology company developing vaccine and antibody-based therapies as a way to prevent recurrent cancer, says it has received a follow-on grant of $1.1 million under the Small Business Technology Transfer Program from the National Cancer Institute. Privately held MabVax is developing a human monoclonal antibody therapy to target the carbohydrate antigen sLeA, which is expressed by colon, pancreatic, and breast cancer cells. The antigen sLeA is believed to play an important role in cell adhesion and on the metastatic potential of these cancers.